We are recruiting patients for the Novartis CVHB937A12201 Study
The Novartis VHB937A12201 study is a Phase 2 clinical trial testing an investigational therapy called VHB937 for people with early to moderate Alzheimer’s disease. Participants receive monthly intravenous infusions of VHB937 or a placebo over approximately 72 weeks. The treatment is designed to target immune processes in the brain that may help slow disease progression. Participation includes monthly infusions, quarterly cognitive and physical assessments, and occasional MRI or PET scans. Those who complete the initial phase may continue into an extension portion of the study.
Who is eligible?
We are looking for people who are 50-85 years of age and have:
- A diagnosis of mild cognitive impairment due to AD or mild AD according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria.
- A Clinical Dementia Rating global score of 0.5 or 1.0 at screening and baseline.
- A reliable study partner who spends sufficient time with the participant on a regular basis, and is willing and able to attend study visits and answer questions about the participant.
And those who do not have:
- Dementia due to a condition other than AD.
- Prior or current treatment with an anti-amyloid antibody, such as lecanemab.
- Stroke or transient ischemic attack in the past 12 months.
What is involved?
- Study visits every 4 weeks.
- A 72-week double-blind treatment period - VHB937 or placebo.
- An open-label extension, lasting between 96 weeks and 6 years.
For more information, please contact:
Study Coordinator: Bailey Wolf, 253-266-5505 or bwolf3@uw.edu
